Kardigan secures $400 million IPO to fund three clinical-stage cardiovascular candidates
read at Endpoints ↗DealPositive
Kardigan, a New Jersey biotech focused on heart disease, announced it raised $400 million in a Nasdaq initial public offering.
The capital will be directed toward advancing three clinical-stage drug candidates that aim to treat various cardiovascular conditions.
The strong demand for the shares highlights ongoing investor confidence in biotech offerings, even as broader market conditions remain uncertain.
Kardigan plans to begin trading on Nasdaq on Thursday, positioning the new funding to support later‑stage trials and potential commercialization efforts.
source
This writeup was produced by pharmadog from original reporting by Endpoints.
Original headline: “Kardigan raises $400M in IPO to back three clinical-stage cardio drugs”
read at Endpoints ↗88 words · retrieved Jun 18
comments(0)
5-min edit window · permanent after that